News

Coventry & Birmingham, UK – 11 Feb 2026 – Histofy, a leading UK-based pathology AI company, is pleased to announce that it has signed a contract with the West Midlands Secure Data Environment (WMSDE) to support advanced annotation and AI-driven enrichment of whole-slide images. As part of this agreement, Histofy will provide access to its […]

Coventry, UK and Vista, CA (6th September 2025) – Histofy, a leading innovator in AI-powered pathology, today announced a customer-centric collaboration with Leica Biosystems, a global leader in anatomic and digital pathology solutions. Under this agreement, Leica Biosystems will act as a reseller and incorporate Histofy’s AI solutions, starting with MitPro®, Histofy’s next-generation mitosis profiling

Histofy has been certified to ISO/IEC 27001 and ISO 13485, marking a major milestone in its commitment to excellence. The company now meets globally recognised standards for information security and medical device quality management. This achievement reinforces Histofy’s role in delivering trusted, high-performance AI solutions for healthcare. Coventry, UK (9 July 2025) – Histofy, a

Histofy and Fundación MD Anderson Cancer Center España announce exclusive partnership to advance AI-driven cancer diagnostics with support of Smart In Media Coventry, UK and Madrid, Spain  (4th June 2025) – Histofy, a leading pathology AI company focused on transforming cancer diagnostics, today announced a landmark exclusive partnership with Fundación MD Anderson Cancer Center España,

Histofy and Source BioScience Announce Strategic Partnership to Advance AI-Powered Pathology in the UK. Coventry & Nottingham, UK (6 May 2025) — Histofy, a leading UK based pathology AI company focused on accelerating histopathology workflows in both clinical and pharmaceutical sectors, is proud to announce a strategic partnership with Source BioScience UK Limited, the largest

Cancer Research Horizons non-exclusively licenses multi-modal S:CORT dataset to enable Histofy to develop AI-based digital pathology tools that stratify colorectal cancer patients based on risk and predict treatment response. These software solutions will help to select the best therapeutic option for each patient, aiming to improve outcomes by enabling the personalised treatment of colorectal cancer.

Histofy, an AI-driven leader in histopathology solutions, is excited to announce a new collaboration with Haukeland University Hospital (HUH), one of Norway’s premier medical institutions. The partnership aims to address a critical challenge in modern pathology: the classification of colon polyps. This initiative promises to improve efficiency, assisting pathologists in making quicker assessments for colorectal

Histofy, a leader in the development of transparent AI solutions for pathology, proudly announces the formation of its Scientific Advisory Board. This milestone reflects Histofy’s commitment to integrating world-class expertise into its innovative product line, ensuring real-world impact. Coventry, UK (22nd July 2024) – Histofy is pleased to introduce its new Scientific Advisory Board, comprising

Lumiares, a Belgium-based healthtech venture capital fund, announces an investment in Histofy, a University of Warwick spin-out dedicated to the creation of transparent AI solutions for cellular pathology. Ghent, Belgium and Coventry, UK (10th July 2024) – Lumiares takes great pride in announcing its investment in Histofy, a spin-out from the distinguished Tissue Image Analytics

Histofy, a biomedical technology company specialising in AI solutions for pathology, proudly announces a partnership with Indica Labs, a leader in AI-powered image analysis and collaborative image management platforms. This strategic alliance marks a significant milestone, aiming to seamlessly integrate Histofy’s advanced AI tools into the HALO AP® platform, developed by Indica Labs. Birmingham, UK